1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Eisai and Biogen Idec pool Alzheimer's efforts

 
• By Sukaina Virji

Eisai and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai's clinical pipeline candidates for Alzheimer's disease, E2609 and BAN2401. The agreement also gives Eisai an option to jointly develop and commercialize two of Biogen Idec's candidates for Alzheimer’s disease, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

Eisai and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai's clinical pipeline candidates for Alzheimer's disease, E2609 and BAN2401. The agreement also gives Eisai an option to jointly develop and commercialize two of Biogen Idec's candidates for Alzheimer’s disease, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

Eisai has been taking a series of steps in recent months to reduce costs and employee numbers as it looks...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Neurological

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.